Clinically Deployable Platform PRIMAB-Dx is a CLIA validated functional biomarker platform for guiding apoptosis targeted therapies in AML and other hematologic cancers, enabling a direct RUO to CLIA revenue path for pharma trials.

Strategic Collaborations Strong ongoing collaborations with MD Anderson, USC Keck, MGH, and NUS provide access to trial networks and translational resources. Opportunity: leverage these relationships to run multi center studies and generate real world case studies to de risk partnerships.

Global Expansion Recent collaboration with the National University of Singapore signals readiness for international deployment, offering potential to support global trials and cross border biomarker testing.

Funding Model Historically supported by over 21M in non dilutive funding and current revenue streams, the company uses a scalable RUO to CLIA model that fits pharma testing services and future licensing.

Market Positioning Focused on functional precision oncology that aligns therapy with tumor physiology rather than disease label, Eutropics differentiates from traditional assays and positions as a biomarker driven partner for BH3 mimetic trials and companion diagnostics.